Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.46 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.43 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.43 |
| ▸ | KIF11 | P52732 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20553269 | 0.81 | RXFP1 (0.58) | RXFP1PTGS1SIRT2MAPK8SMN1; SMN2 | |
| SCHEMBL22571369 | 0.81 | SIRT2 (0.62) | RXFP1PTGS1SIRT2MAPK8TAS2R14 | |
| SCHEMBL22556306 | 0.80 | RXFP1 (0.53) | RXFP1PTGS1SIRT2MAPK8SMN1; SMN2 | |
| SCHEMBL22635632 | 0.78 | TEAD1 (0.48) | AKR1C3AKR1C2 | |
| SCHEMBL4245559 | 0.77 | MAPK8 (0.67) | RXFP1PTGS1MAPK8TAS2R14AKR1C3 | |
| SCHEMBL25279533 | 0.76 | AKR1C3 (0.60) | RXFP1PTGS1SIRT2MAPK8SMN1; SMN2 | |
| SCHEMBL21764748 | 0.76 | RXFP1 (0.47) | RXFP1PTGS1SIRT2MAPK8SMN1; SMN2 | |
| SCHEMBL22556324 | 0.75 | RXFP1 (0.48) | RXFP1PTGS1SIRT2MAPK8SMN1; SMN2 | |
| SCHEMBL21765032 | 0.73 | MAPT (0.69) | RXFP1SIRT2MAPK8TAS2R14POLB | |
| SCHEMBL23701538 | 0.72 | RXFP1 (0.51) | RXFP1PTGS1MAPK8SMN1; SMN2ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885PTGS1 2113/4885SIRT2 1044/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | RXFP1 3511/4885PTGS1 2113/4885SIRT2 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.